It’s important to be a proactive PNH patient. You’ll want to know how to how to find a doctor and manage your treatment.

PNH is a rare, chronic, and life-threatening blood disease in which uncontrolled complement activation leads to the destruction of red blood cells through intravascular hemolysis and ...

Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician preferences, and the impact of biosimilar ...

Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria ...

Patients with paroxysmal nocturnal hemoglobinuria (PNH) who had suboptimal response to eculizumab can switch to pegcetacoplan for a cost-effective alternative, according to. acost analysis.

Pegcetacoplan, a complement 3 (C3) inhibitor, was shown to be more cost-effective for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) than eculizumab and ravulizmab, both complement 5 ...

Inhibitors of proximal and terminal complement cascades can often control red-cell hemolysis associated with paroxysmal nocturnal hemoglobinuria, but some patients have breakthrough hemolysis.

NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy ...

Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH ...

In PNH, Severe Hemolysis Post COVID-19 Vaccination is Possible —An absence of complement regulatory proteins in patients with paroxysmal nocturnal hemoglobinuria could trigger adverse reactions ...

This first-in-class, oral Factor D inhibitor can now be used as an add-on to ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with residual haemolytic ...

Novartis NVS announced that the late-stage APPOINT-PNH study (NCT04820530) evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults ...